In this review, we consider new concepts in the assessment of fracture risk and pharmacologic therapy for osteoporosis. We discuss trabecular bone score, a new imaging technology that adds information that cannot be obtained by only measuring bone mineral density by dual-energy x-ray absorptiometry. We also discuss innovations in antiresorptive, osteoanabolic, and combination therapy; and newer therapeutic classes, including cathepsin K inhibitors and antisclerostin antibodies. We do not cover agents that have not yet been studied in human clinical trials or that are no longer under active investigation.
Department of Medicine, Metabolic Bone Diseases Unit, College of Physicians and Surgeons, Columbia University, New York, New York
Supported by NIH DK069350, NIH DK32333, and FDA 002525.
J.P.B. is a consultant for Amgen, Eli Lilly, Radius, NPS Pharmaceuticals, Merck, Warner Chilcott, and GSK, and receives research support from NPS Pharmaceuticals and Amgen. The remaining authors declare that they have nothing to disclose.
Correspondence: John P. Bilezikian, MD, Department of Medicine, College of Physicians and Surgeons, New York, NY. E-mail: firstname.lastname@example.org